About regorafen ib
Multikinase inhibitor anticancer medicine
Used for
- Treats colorectal cancer that has spread, after other treatments.
- Treats gastrointestinal stromal tumors after other treatments.
- Treats liver cancer previously treated with sorafenib.
Usual adult dose
160 mg once daily for 21 days, then 7 days off, in repeating 28-day cycles; dose may be adjusted.
Common side effects
- Tiredness, diarrhea, mouth sores, and reduced appetite.
- Hand-foot skin reaction, rash, and high blood pressure.
- Liver problems, bleeding, and infections.
Important warnings
- Can cause severe or fatal liver injury; liver tests require monitoring.
- May cause serious bleeding, high blood pressure, or heart problems.
- Can impair wound healing; treatment may need pausing around surgery.
- Use effective contraception; may harm an unborn baby.
Pregnancy
May cause fetal harm. Avoid during pregnancy; use effective contraception during treatment and for two months afterward.
Breastfeeding
Do not breastfeed during treatment and for two weeks after the final dose.
Interactions
- Strong CYP3A4 inhibitors can increase regorafenib exposure.
- Strong CYP3A4 inducers can reduce its effectiveness.
- May increase exposure to some medicines, including warfarin and certain statins.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.